Biogen Idec, Inc. (BIIB) Tops Q2 EPS by 37c; Issues Solid Guidance StreetInsider.com (subscription) ... generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. |
